Congratulations to our #TeamBicycle colleague Jennifer Perry, PharmD on her promotion to Chief Strategy Officer! Jennifer will oversee our corporate and end-to-end portfolio strategy while also fulfilling her existing responsibilities as Head of Commercial. We look forward to seeing Jennifer succeed in this expanded and elevated role.
Bicycle Therapeutics
Biotechnology Research
Cambridge, England 30,643 followers
Precision-Guided Therapeutics
About us
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA.
- Website
-
https://www.bicycletherapeutics.com
External link for Bicycle Therapeutics
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Cambridge, England
- Type
- Public Company
- Founded
- 2009
- Specialties
- Drug Discovery, Phage Display, Peptide Therapeutics, and Biotechnology
Locations
-
Primary
Get directions
Granta Park
Cambridge, England CB21 6GP, GB
-
Get directions
35 Cambridgepark Dr
Cambridge, Massachusetts 02140, US
Employees at Bicycle Therapeutics
Updates
-
We recently held our UK #Science Fair, an annual event hosted by our #Research Team to showcase the innovative work being conducted at Bicycle Therapeutics. Out of 25 posters highlighting the breadth and potential of our Bicycle® platform, congrats to Amin Sagar, Alexandra Kaupisch and Steven Stanway; LAURA DIAZ GIL; and Shenaz Allyjaun, Hector Newman and Emily Beddows for winning this year's competition. And a big thank you to the organizing committee, led by Mark Frigerio and Inma Rioja.
-
-
At Bicycle Therapeutics, we are harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines for #cancer and other diseases. Watch this video to learn more.
-
We’re welcoming our most recent new hires who joined #TeamBicycle in June. We are excited to have you on our Clinical Operations, CMC and Medical Affairs teams! Learn more about our careers and culture: https://bit.ly/3TS7ZA8.
-
-
Today our CFO Alethia Young joined FT Live’s "Funding #Biopharma #Innovation" event, where she offered her thoughts on the need for companies to be creative in this current funding environment so our industry can continue its vital work to bring novel therapies to patients. Thanks to Oliver Barnes and panelists for a lively and insightful discussion. Replay: https://lnkd.in/dwZDHSK3. #FTHealth Photo credit: FT Live
-
-
Three investor conferences in three weeks – what a whirlwind! Thanks to Jefferies, Goldman Sachs and Cowen Inc. for hosting our team and for the opportunity to discuss our work to develop therapies for #cancer. Replays of the fireside chats and presentations are available on our website: https://bit.ly/4eldP6n.
-
-
Our CEO Kevin Lee recently spoke to Biotech Strategy Blog's Sally Church about how we're harnessing the power of bicyclic peptides to develop a variety of highly specific, targeted therapies to treat #cancer and other diseases. Read more here: https://bit.ly/4aVjkGc.
-
-
We’re welcoming our most recent new hires who joined #TeamBicycle in May. We are excited to have you on our Clinical, Medical and Finance teams! Learn more about our careers and culture: https://bit.ly/3TS7ZA8.
-
-
We’re excited to join the #oncology community at #ASCO24. Stop by our posters about the emerging differentiated safety and tolerability profiles of our Bicycle® molecules and our Phase 2/3 Duravelo-2 trial for #bladdercancer. See you soon: https://bit.ly/44V0hu6 #cancer #solidtumors
-
We are pleased to announce our $555 million financing that will support the ongoing progress of our pipeline of precision-guided therapeutics. A big thanks to our new and existing investors for their confidence in our team and the potential of our Bicycle® platform to create innovative new medicines for #cancer and other diseases. We believe this brings us one step closer to achieving our vision of helping patients live longer and live well. Read the news: https://bit.ly/44RO2OU
-